Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

One theory on Ariflo difficulties

Executive Summary

Variable results seen in clinical trials of the PDE4 inhibitor Ariflo for chronic obstructive pulmonary disease may be due to patient selection, GSK VP-New Product Development James Palmer speculates during Goldman Sachs conference. "I think you are seeing some probably asthmatic patients or other types of patients getting into these studies who have some reversibility, which probably accounts for some of the variable results that you are seeing," Palmer said. Development of Ariflo was delayed after a pivotal European trial failed to reach statistical significance (1"The Pink Sheet" Nov. 6, 2000, p. 4). A follow-up study is recruiting patients and one-year data is expected to be filed in the second half of 2002, Palmer said. GSK's Advair (salmeterol/fluticasone) was filed for COPD in May

You may also be interested in...



SB Paxil Exclusivity Defense: Synthon Files NDA For Paroxetine Mesylate

SmithKline Beecham could face competition to its antidepressant Paxil in the U.S. from an NDAed version of a different salt of paroxetine filed by Synthon.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
UsernamePublicRestriction

Register

PS038083

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel